TUCSON, Ariz., July 22, 2025 — Stakeholders across the life sciences ecosystem are invited to attend the 2025 Critical Path Institute® (C-Path) Global Impact Conference (CGIC), taking place Sept. 9–11 ...

Critical Path Institute’s® Critical Path for Alpha-1 Antitrypsin Deficiency Consortium today announced the addition of AIRNA as its newest industry partner, bringing RNA editing expertise to the ...

By David Bautz, PhD NASDAQ: ASBP Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) is attempting something relatively uncommon ...

Global initiative to scale advanced therapeutic treatments to accelerate patient access worldwide. TUCSON, Ariz. and AMSTERDAM, March 26, 2026 /PRNewswire/ -- Critical Path Institute® (C-Path) today ...

Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...

The Tucson-based Critical Path Institute was founded in 2005 as a public-private partnership with the U.S. Food and Drug Administration. Its main goal is to improve the drug-development process so ...

Tucson's Critical Path Institute recently got some good news - and some noteworthy recognition - when the U.S. Senate gave final approval to a budget reauthorization bill including the Food and Drug ...

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

Venture Partners at CU Boulder has announced the first recipients of a new translational funding program designed to advance promising, early-stage therapeutics with strong commercial potential. The ...

Wanted: a cheap, multipotent treatment for viral infections. Must be able to handle new or unfamiliar strains, or (even ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.